{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-029239","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.562832+00:00","generated_at":"2026-06-04T23:57:08.215336+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ORIC Pharma Q4 2023: R&D expenses up to $24.5M; cash $235M; pipeline progress on ORIC-944/114","bullets":["Q4 2023 R&D expenses $24.5M (up $8.2M YoY); G&A $6.9M; cash and investments $235M at Dec 31, 2023.","Two private placements raised $85M (June 2023) and $125M (Jan 2024); pro forma cash $351.8M at Jan 31, 2024, funding into late 2026.","Initial Phase 1b data for ORIC-114 (EGFR/HER2) and ORIC-944 (PRC2) show best-in-class potential; dose expansion for ORIC-114 in mutated NSCLC expected H1 2024.","ORIC-533 (CD73 inhibitor) Phase 1b dose escalation completed Q1 2024; company plans strategic partnership for combination studies.","ORIC-944 combination study with AR inhibitor to start H1 2024; program update mid-2024. Discovery includes PLK4 inhibitor ORIC-613 advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-029239","json":"https://secwatch.observer/filing/0000950170-24-029239.json","markdown":"https://secwatch.observer/filing/0000950170-24-029239.md","text":"https://secwatch.observer/filing/0000950170-24-029239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/0000950170-24-029239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/oric-20240311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:57:08.215336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d79ce891b55a4594c4da333524e826f9b126625e","claim":"Oric Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 11, 2024, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024029239/0000950170-24-029239-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}